Line 64: | Line 64: | ||
<div class="container"> | <div class="container"> | ||
<div class="mb-5 text-center"> | <div class="mb-5 text-center"> | ||
+ | <br> | ||
<h3 class="heading h3">This is CAPOEIRA</h3> | <h3 class="heading h3">This is CAPOEIRA</h3> | ||
</div> | </div> | ||
</div> | </div> | ||
− | <img width="100%" src="https://static.igem.org/mediawiki/2018/8/8d/T--EPFL--desc.svg"> | + | <div class="row row-grid align-items-center mt--100"> |
+ | <img width="100%" src="https://static.igem.org/mediawiki/2018/8/8d/T--EPFL--desc.svg"> | ||
+ | </div> | ||
+ | |||
</section> | </section> | ||
Revision as of 18:33, 12 October 2018
CAPOEIRA
Cancer Personalized Encapsulin Immunotherapy and Relapse Assay
Learn more about our projectWhat is CAPOEIRA ?
While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to retaliate!
This is CAPOEIRA